1597 related articles for article (PubMed ID: 30841472)
1. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
2. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
4. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
6. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats.
Yin Y; Liu H; Zheng Z; Lu R; Jiang Z
Biomed Pharmacother; 2019 Mar; 111():1290-1296. PubMed ID: 30841442
[TBL] [Abstract][Full Text] [Related]
7. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
8. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
[TBL] [Abstract][Full Text] [Related]
11. [Preventive and therapeutic effects of compound ginkgo extract in rats with nonalcoholic steatohepatitis induced by high-fat, high-fructose diet].
Yang Q; Zhao H; Zhou AZ; Lou ZH
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):852-858. PubMed ID: 27978932
[No Abstract] [Full Text] [Related]
12. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
Ren T; Zhu J; Zhu L; Cheng M
Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
[TBL] [Abstract][Full Text] [Related]
13. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
14. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
[TBL] [Abstract][Full Text] [Related]
15. [Effect of apigenin on protein expressions of PPARs in liver tissues of rats with nonalcoholic steatohepatitis].
Shi T; Zhuang R; Zhou H; Wang F; Shao Y; Cai Z
Zhonghua Gan Zang Bing Za Zhi; 2015 Feb; 23(2):124-9. PubMed ID: 25880979
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949
[TBL] [Abstract][Full Text] [Related]
17. Conophylline inhibits non-alcoholic steatohepatitis in mice.
Nakade Y; Sakamoto K; Yamauchi T; Inoue T; Kobayashi Y; Yamamoto T; Ishii N; Ohashi T; Sumida Y; Ito K; Nakao H; Fukuzawa Y; Umezawa K; Yoneda M
PLoS One; 2017; 12(6):e0178436. PubMed ID: 28594915
[TBL] [Abstract][Full Text] [Related]
18. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
[TBL] [Abstract][Full Text] [Related]
19. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
